AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31811007 — intervention group
Group type: EXPERIMENTAL
Intervention: burr hole cover
Number of subjects: 80
Study 31811007 — intervention group
Group type: COMPARATOR
Intervention: no burr hole cover
Number of subjects: 80
Study 27710137 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-client interaction
Number of subjects: 418
Study 26531124 — intervention group
Group type: EXPERIMENTAL
Intervention: MemFlex
Number of subjects: 50
Study 26531124 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (Control)
Number of subjects: 50
Study 23318707 — intervention group
Group type: EXPERIMENTAL
Intervention: Service user-researcher
Number of subjects: 161
Study 23318707 — intervention group
Group type: COMPARATOR
Intervention: Clinician
Number of subjects: 161
Study 21237383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG
Number of subjects: 425
Study 21237383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG (Male)
Number of subjects: 425
Study 21237383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG (Female)
Number of subjects: 425
Study 21237383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG (Overall)
Number of subjects: 425
Study 18936284 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 6 mg/day
Number of subjects: 19
Study 18936284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17540797 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Start (immediate, directly observed ingestion of the first pill during the clinic visit)
Number of subjects: 1716
Study 17540797 — intervention group
Group type: COMPARATOR
Intervention: Conventional Start (waiting until menses to start the oral contraceptive pill)
Number of subjects: 1716
Study 17540797 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Start
Number of subjects: 1716
Study 17540797 — intervention group
Group type: COMPARATOR
Intervention: Quick Start and Conventional Start
Number of subjects: 1716
Study 15467969 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressive treatment for 35 days
Number of subjects: 24
Study 15467969 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up (> 12 months)
Number of subjects: 24
Study 11179527 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose of amiodarone (three 200-mg Cordarone tablets) after an overnight fast
Number of subjects: 30
Study 11179527 — intervention group
Group type: COMPARATOR
Intervention: Single-dose of amiodarone (three 200-mg Cordarone tablets) after a standard high-fat breakfast
Number of subjects: 30
Study 9530364 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (40 micrograms/kg) infused for 30 minutes before CDDP infusion (standard method)
Number of subjects: 41
Study 9530364 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron mixed with CDDP and infused over 0.5-3 hours (simultaneous method)
Number of subjects: 41
Study 8017591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propofol (0.3 microgram.ml‐1, 0.6 microgram.ml‐1, 0.9 microgram.ml‐1)
Number of subjects: 28
Study 8017591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propofol
Number of subjects: 28
Study 2722727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole
Number of subjects: 128
Study 2722727 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 128
Study 31053896 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based composite (Spectrum TPH3)
Number of subjects: 260
Study 31053896 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer (Dyract Posterior)
Number of subjects: 260
Study 31053896 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O inhalation sedation or general anesthesia
Number of subjects: 260
Study 31053896 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal-occlusal compomer restorations
Number of subjects: 260
Study 30428913 — intervention group
Group type: EXPERIMENTAL
Intervention: CASS system
Number of subjects: 60
Study 30428913 — intervention group
Group type: COMPARATOR
Intervention: Conventional sleeve
Number of subjects: 60
Study 28025062 — intervention group
Group type: EXPERIMENTAL
Intervention: e-feedback after video observation of surgical suturing
Number of subjects: 38
Study 28025062 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal feedback after direct observation
Number of subjects: 38
Study 28025062 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststudy questionnaire for e-feedback
Number of subjects: 38
Study 28025062 — intervention group
Group type: COMPARATOR
Intervention: Poststudy questionnaire for standard verbal feedback
Number of subjects: 38
Study 26551748 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic riding
Number of subjects: 26
Study 26551748 — intervention group
Group type: COMPARATOR
Intervention: Non-riding control group
Number of subjects: 26
Study 23875838 — intervention group
Group type: EXPERIMENTAL
Intervention: Theatre-arts intervention taught by in-house activity directors with no formal training in theatre
Number of subjects: 115
Study 23875838 — intervention group
Group type: EXPERIMENTAL
Intervention: Theatre-arts intervention taught by a professional acting teacher with minimal training
Number of subjects: 115
Study 21203878 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% preservative-free 2-chloroprocaine 40 mg
Number of subjects: 106
Study 21203878 — intervention group
Group type: COMPARATOR
Intervention: 0.75% hyperbaric bupivacaine 7.5 mg
Number of subjects: 106
Study 18471639 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of gatifloxacin in the dilating mixture
Number of subjects: 100
Study 18471639 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of moxifloxacin in the dilating mixture
Number of subjects: 100
Study 18471639 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of gatifloxacin in the dilating mixture
Number of subjects: 100
Study 18471639 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of moxifloxacin in the dilating mixture
Number of subjects: 100
Study 18471639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (gatifloxacin and moxifloxacin)
Number of subjects: 100
Study 16841628 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy
Number of subjects: 174
Study 16841628 — intervention group
Group type: COMPARATOR
Intervention: Intensive clinical management approach
Number of subjects: 174
Study 14623834 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral dexketoprofen trometamol
Number of subjects: 122
Study 14623834 — intervention group
Group type: COMPARATOR
Intervention: 50 mg sodium diclofenac
Number of subjects: 122
Study 10934667 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (20-1000 mg single dose or 50-500 mg bid for 7 days)
Number of subjects: 72
Study 10934667 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (100-200 mg bid for 7 days)
Number of subjects: 72
Study 10934667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 9059203 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES 200/0.5)
Number of subjects: 46
Study 9059203 — intervention group
Group type: COMPARATOR
Intervention: 3% modified fluid gelatin (MFG)
Number of subjects: 46
Study 8442438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent, cyclic etidronate (400 mg/day for 2 weeks followed by 13 weeks free from study drug administration)
Number of subjects: 66
Study 8442438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 8442438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent, cyclic etidronate
Number of subjects: 66
Study 3801827 — intervention group
Group type: EXPERIMENTAL
Intervention: Local instillation of fibrin adhesive (Beriplast)
Number of subjects: 30
Study 3801827 — intervention group
Group type: COMPARATOR
Intervention: No special treatment post-operatively (Control)
Number of subjects: 30
Study 30880938 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 µg
Number of subjects: 3394
Study 28918877 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg once daily with tenofovir disoproxil fumarate and emtricitabine
Number of subjects: 802
Study 28918877 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily with tenofovir disoproxil fumarate and emtricitabine
Number of subjects: 802
Study 28918877 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg once daily
Number of subjects: 802
Study 28918877 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 802
Study 26351350 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 815
Study 26351350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815
Study 26351350 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide Vaccination (PV)
Number of subjects: 815
Study 26351350 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF with resected visceral metastases
Number of subjects: 815
Study 23061402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid cycle training (hand cycling combined with functional electrical stimulation-induced leg cycling)
Number of subjects: 40
Study 23061402 — intervention group
Group type: COMPARATOR
Intervention: Hand cycle training (control group)
Number of subjects: 40
Study 21943352 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel milk protein peptide (MP) mixture
Number of subjects: 73
Study 21943352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 19782784 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal exercise program in addition to optimal medical therapy
Number of subjects: 2331
Study 19782784 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone without any formal exercise training
Number of subjects: 2331
Study 17716260 — intervention group
Group type: EXPERIMENTAL
Intervention: Before sintering
Number of subjects: 10
Study 17716260 — intervention group
Group type: EXPERIMENTAL
Intervention: After sintering
Number of subjects: 10
Study 17716260 — intervention group
Group type: COMPARATOR
Intervention: Before/After sintering
Number of subjects: 10
Study 12923144 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate-containing product (SpermCatch)
Number of subjects: 0
Study 12923144 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-containing product (ICSI-100)
Number of subjects: 0
Study 12923144 — intervention group
Group type: COMPARATOR
Intervention: Control group (sperm maintenance medium)
Number of subjects: 0
Study 10632686 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice daily started the morning before the procedure
Number of subjects: 84
Study 10632686 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice daily started the morning of the procedure
Number of subjects: 84
Study 8862639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 2 micrograms.kg‐1.min‐1
Number of subjects: 7
Study 8862639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 6 micrograms.kg‐1.min‐1
Number of subjects: 7
Study 1340938 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg/day)
Number of subjects: 36
Study 1340938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6359471 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin treatment for four weeks
Number of subjects: 41
Study 6359471 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin treatment for over one year
Number of subjects: 41
Study 6359471 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin treatment after discontinuation
Number of subjects: 41
Study 4011138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic saline solution (150 mOsm/L)
Number of subjects: 20
Study 4011138 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 20
Study 4011138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic saline solutions (75-225 mOsm/L)
Number of subjects: 20
Study 29058022 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury-prevention programme (neuromuscular exercises) for one season
Number of subjects: 279
Study 29058022 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 279
Study 27179720 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380
Study 27179720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study 24502822 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month care coordination intervention
Number of subjects: 303
Study 24502822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 303
Study 23025736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-GP partnership intervention
Number of subjects: 451
Study 23025736 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 451
Study 20008425 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 46
Study 20008425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 18082676 — intervention group
Group type: EXPERIMENTAL
Intervention: Human infants
Number of subjects: 0
Study 18082676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton-top tamarin monkeys
Number of subjects: 0
Study 16601504 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visiting programs by professionals
Number of subjects: 0
Study 16601504 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 12950328 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen replacement therapy
Number of subjects: 71
Study 12950328 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (placebo control)
Number of subjects: 71
Study 11126150 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder-sphincter-biofeedback training
Number of subjects: 31
Study 11126150 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercise
Number of subjects: 31
Study 8823677 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic timing device to measure drive phase time
Number of subjects: 17
Study 8823677 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic timing device to measure recovery phase time
Number of subjects: 17
Study 1442656 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg/d iron supplement and a low food-iron diet (50 FE + EX)
Number of subjects: 47
Study 1442656 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg/d iron supplement and a low food-iron diet (10 FE + EX)
Number of subjects: 47
Study 1442656 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and unrestricted diet (P + EX)
Number of subjects: 47
Study 1442656 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat supplement and high food-iron diet (M + EX)
Number of subjects: 47
Study 1442656 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (n = 13)
Number of subjects: 47
Study 6535823 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial epicondylectomy and external decompression with steroid therapy
Number of subjects: 44
Study 6535823 — intervention group
Group type: COMPARATOR
Intervention: Steroid therapy alone
Number of subjects: 44
Study 31208376 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app and TAU (treatment as usual)
Number of subjects: 260
Study 31208376 — intervention group
Group type: COMPARATOR
Intervention: TAU without the smartphone app
Number of subjects: 260
Study 30279091 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised letter
Number of subjects: 5534
Study 30279091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet
Number of subjects: 5534
Study 30279091 — intervention group
Group type: COMPARATOR
Intervention: Control (no direct communication)
Number of subjects: 5534
Study 27240158 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink
Number of subjects: 0
Study 27240158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27240158 — intervention group
Group type: COMPARATOR
Intervention: Panax ginseng
Number of subjects: 0
Study 24768633 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SQ) injection of anthrax vaccine adsorbed (AVA)
Number of subjects: 1563
Study 24768633 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) injection of anthrax vaccine adsorbed (AVA)
Number of subjects: 1563
Study 24768633 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SQ) injection of anthrax vaccine adsorbed (AVA) in obese participants
Number of subjects: 1563
Study 24768633 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants receiving AVA
Number of subjects: 1563
Study 24768633 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with highest anti-PA IgG concentrations
Number of subjects: 1563
Study 24768633 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants receiving AVA
Number of subjects: 1563
Study 24768633 — intervention group
Group type: EXPERIMENTAL
Intervention: Women-only subset analysis
Number of subjects: 1563
Study 22503739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multifactorial falls prevention program
Number of subjects: 156
Study 22503739 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 156
Study 20466657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) - two doses at 15 mg/kg to a maximum of 750 mg per dose
Number of subjects: 2500
Study 20466657 — intervention group
Group type: COMPARATOR
Intervention: Venofer(R) - 1000 mg administered as five infusions of 200 mg
Number of subjects: 2500
Study 18155993 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted-carbohydrate diets
Number of subjects: 13
Study 16362853 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary angioplasty (PTCA)
Number of subjects: 63
Study 16362853 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical coronary artery bypass grafting (CABG)
Number of subjects: 63
Study 16362853 — intervention group
Group type: COMPARATOR
Intervention: Control group (CABG in younger patients)
Number of subjects: 63
Study 16362853 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes for octogenarians
Number of subjects: 63
Study 16362853 — intervention group
Group type: COMPARATOR
Intervention: Overall outcomes for younger patients
Number of subjects: 63
Study 12431318 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 16
Study 12431318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10226853 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal NTG (0.6 mg/h)
Number of subjects: 20
Study 10226853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual NTG after 5 days of sustained transdermal NTG therapy (0.6 mg/h)
Number of subjects: 20
Study 10226853 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin C (2 g)
Number of subjects: 20
Study 10226853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8902425 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage galvanic stimulation of ST36 and ST37 acupuncture points
Number of subjects: 11
Study 8902425 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 11
Study 1860385 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan 3.0g/day for six weeks
Number of subjects: 79
Study 1860385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 6617066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (median dosage 15 mg/day or 5 mg per 25 mg hydrochlorothiazide)
Number of subjects: 0
Study 6617066 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (continued therapy)
Number of subjects: 0
Study 6617066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (adjunctive treatment)
Number of subjects: 0
Study 31229396 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session, 6-month director's child nutrition course with on-site technical support for center teachers
Number of subjects: 408
Study 31229396 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 408
Study 28484877 — intervention group
Group type: EXPERIMENTAL
Intervention: Two NSAIDs (diclofenac and celecoxib) with morphine sulfate 10 mg/12 h
Number of subjects: 342
Study 28484877 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac with morphine sulfate 10 mg/12 h
Number of subjects: 342
Study 28484877 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib with morphine sulfate 10 mg/12 h
Number of subjects: 342
Study 26388272 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg etomidate IV (Group I)
Number of subjects: 60
Study 26388272 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg etomidate IV following 2 mg/kg methylprednisolone IV (Group II)
Number of subjects: 60
Study 26388272 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg IV midazolam (Group III)
Number of subjects: 60
Study 24279592 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (TEA plus standard care)
Number of subjects: 40
Study 24279592 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 40
Study 21127883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutathione (GSH) 100 mg/min for 30 min before CAG
Number of subjects: 21
Study 21127883 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 21
Study 21127883 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 21127883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutathione (GSH)
Number of subjects: 21
Study 19843054 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐beta‐CD formulation at 1, 10, 30 microg
Number of subjects: 16
Study 19843054 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐beta‐CD formulation at 100 microg
Number of subjects: 16
Study 19843054 — intervention group
Group type: COMPARATOR
Intervention: Tween formulation at 100 microg
Number of subjects: 16
Study 19843054 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 16
Study 17928994 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glucose control group (SGC) with a blood glucose target of 4-6 mmol/l
Number of subjects: 90